Timothy S. Huval Sells 3,703 Shares of Humana Inc. (NYSE:HUM) Stock

Humana Inc. (NYSE:HUM) insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Humana Price Performance

Shares of HUM traded up $10.79 during midday trading on Friday, reaching $263.44. The stock had a trading volume of 566,758 shares, compared to its average volume of 707,672. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The company has a market capitalization of $31.72 billion, a P/E ratio of 23.33, a P/E/G ratio of 2.12 and a beta of 0.53. The firm’s 50 day moving average price is $272.56 and its 200-day moving average price is $314.60. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $471.37.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping the consensus estimate of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The firm had revenue of $29.30 billion for the quarter, compared to analysts’ expectations of $28.66 billion. On average, analysts forecast that Humana Inc. will post 16.14 earnings per share for the current fiscal year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.34%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana’s payout ratio is 31.36%.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on HUM shares. Bank of America raised shares of Humana from an “underperform” rating to a “neutral” rating and boosted their price objective for the company from $247.00 to $308.00 in a research report on Wednesday, November 6th. Wells Fargo & Company lowered their target price on Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a report on Monday, November 4th. TD Cowen raised their price target on Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Cantor Fitzgerald restated a “neutral” rating and set a $395.00 price objective on shares of Humana in a research note on Tuesday, October 1st. Finally, Barclays increased their target price on Humana from $250.00 to $253.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Twenty analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Humana has an average rating of “Hold” and a consensus target price of $300.50.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of HUM. Creative Financial Designs Inc. ADV raised its holdings in Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after buying an additional 61 shares during the period. Atwood & Palmer Inc. acquired a new position in Humana in the 3rd quarter worth approximately $29,000. Ashton Thomas Securities LLC purchased a new position in Humana during the 3rd quarter worth approximately $31,000. Your Advocates Ltd. LLP raised its stake in Humana by 81.8% during the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares during the period. Finally, Hollencrest Capital Management purchased a new stake in shares of Humana in the second quarter valued at $40,000. Institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.